查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594152

微量残存疾病检测市场：按技术、适应症和最终用户划分 - 2025-2030 年全球预测

Minimal Residual Disease Testing Market by Technology (Flow Cyclometry, Next-Generation Sequencing, Polymerase Chain Reaction), Indication (Leukemia, Lymphoma, Myeloma), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

微量残存疾病检测市场2023年估值为18.3亿美元，预计到2024年将达到20.5亿美元，复合年增长率为12.36%，预计到2030年将达到41.4亿美元。

微量残存疾病（MRD）检测是指检测和测量治疗后患者体内可能残留的少量癌细胞，以评估癌症復发风险的过程，尤其是在骨髓恶性肿瘤中，这一点极为重要。对 MRD 检测的需求源于其能够更深入地了解治疗效果、为预后评估提供资讯并指导个人化治疗策略。应用程式将主要集中在肿瘤学，特别是白血病、淋巴瘤和骨髓瘤等疾病上，使患者能够接受个人化治疗，并允许临床医生在治疗后做出更明智的决定。最终用途范围包括许多医院、诊断实验室和研究机构投资 MRD 技术以改善患者的治疗结果。

主要市场统计
基准年[2023] 18.3亿美元
预测年份 [2024] 20.5亿美元
预测年份 [2030] 41.4亿美元
复合年增长率（%） 12.36%

根据市场洞察，影响 MRD 检测领域的关键成长要素包括分子诊断技术的进步、血癌盛行率的增加以及精准医疗意识和采用的提高。次世代定序(NGS) 和聚合酵素链锁反应(PCR) 等灵敏、非侵入性技术的发展进一步增强了我们在微小水平上检测残留疾病的能力。透过将MRD检测的应用范围从血液学扩展到固体癌，存在巨大的潜在机会，市场规模可能呈指数级增长。利用这些机会的建议包括开发标准化、检验且成本较低的 MRD 检测方法，以及生物技术公司和研究机构之间建立策略联盟以加速创新。

然而，市场开拓面临挑战，例如与MRD检测技术相关的高成本、新兴市场地区的准入有限以及需要熟练人员解释复杂结果等。此外，不断变化的监管障碍和指南可能会减缓新 MRD 方法的采用。为了实现成长和创新，重点将人工智慧和机器学习整合到 MRD资料分析中可以改变结果的解释，使结果更加准确和用户友好。最终，MRD 检测市场正在迅速发展，如果关键障碍得到策略性解决，则具有相当大的成长潜力。

市场动态：揭示快速发展的微量残存疾病检测市场的关键市场洞察

供需的动态交互作用正在改变微量残存疾病检测市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 需要完善各种癌症的治疗决策
    • 世界人口中骨髓恶性肿瘤的盛行率不断上升
  • 市场限制因素
    • MRD 检测相关的高成本
  • 市场机会
    • 个性化MRD检查技术的演变
    • 持续开发新的微量残存疾病检测方法
  • 市场问题
    • 政府对 MRD 商业化的严格规定

波特五力：驾驭微量残存疾病检测市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对微量残存疾病检测市场的影响

外部宏观环境因素在塑造微量残存疾病检测市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解微量残存疾病检测市场的竞争状况

对微量残存疾病检测市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵：微量残存疾病检测市场供应商绩效评估

FPNV定位矩阵是评估微量残存疾病检测市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製微量残存疾病检测市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对微量残存疾病检测市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 需要改进各种癌症的治疗决策
      • 世界人口中造血系统恶性的盛行率不断增加
    • 抑制因素
      • MRD 检测相关的高成本
    • 机会
      • 个性化MRD检查技术的演变
      • 持续开发新的微量残存疾病检测方法
    • 任务
      • 政府对 MRD 商业化的严格规定
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章微量残存疾病检测市场：依技术分类

  • 介绍
  • 流式循环仪
  • 次世代定序
  • 聚合酵素链锁反应

第七章微量残存疾病检测市场：依适应症分类

  • 介绍
  • 白血病
  • 淋巴瘤
  • 骨髓瘤

第八章微量残存疾病检测市场：依最终用户分类

  • 介绍
  • 学术研究所
  • 诊断实验室
  • 医院

第九章 北美和南美微量残存疾病检测市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太微量残存疾病检测市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东、非洲微量残存疾病检测市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Adaptive BIoTechnologies Corporation
  • Agilus Diagnostics Ltd.
  • Amgen Inc.
  • ARUP Laboratories
  • AstraZeneca PLC
  • Asuragen Inc. by Bio-Techne Corporation
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • C2I Genomics Inc.
  • Cergentis BV
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genetron Holdings Limited
  • GRAIL, LLC by Illumina, Inc.
  • Guardant Health, Inc.
  • Integrated DNA Technologies, Inc.
  • Invivoscribe, Inc.
  • Kite Pharma, Inc. by Gilead Sciences, Inc.
  • Laboratory Corporation of America Holdings
  • Mdxhealth BV
  • MedGenome Inc
  • Mission Bio, Inc.
  • Myriad Genetics, Inc.
  • Natera Inc.
  • NeoGenomics Laboratories, Inc.
  • OPKO Health, Inc.
  • Quest Diagnostics incorporated
  • Sysmex Corporation
  • Veracyte, Inc.
Product Code: MRR-961BA04A2E6C

The Minimal Residual Disease Testing Market was valued at USD 1.83 billion in 2023, expected to reach USD 2.05 billion in 2024, and is projected to grow at a CAGR of 12.36%, to USD 4.14 billion by 2030.

Minimal Residual Disease (MRD) testing refers to the process of detecting and measuring the small number of cancer cells that may remain in a patient after treatment, crucial for assessing the risk of cancer recurrence, particularly in hematologic malignancies. The necessity for MRD testing stems from its ability to provide deeper insights into treatment efficacy, inform prognostic evaluations, and guide personalized treatment strategies. Applications focus primarily within oncology, especially for conditions such as leukemia, lymphoma, and myeloma, ensuring that patients receive tailored care and enabling clinicians to make more informed decisions post-treatment. The end-use scope prominently includes hospitals, diagnostic laboratories, and research institutions investing in MRD technologies to enhance patient outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 1.83 billion
Estimated Year [2024] USD 2.05 billion
Forecast Year [2030] USD 4.14 billion
CAGR (%) 12.36%

Market insights reveal that key growth factors influencing the MRD testing sector include technological advancements in molecular diagnostics, increasing prevalence of hematological cancers, and rising awareness and adoption of precision medicine. The development of sensitive, non-invasive techniques like next-generation sequencing (NGS) and polymerase chain reaction (PCR) has further expanded capabilities in detecting minute levels of residual disease. A significant potential opportunity exists in expanding MRD testing applications beyond hematological to solid tumors, which could drastically enhance its market footprint. Recommendations to capitalize on these opportunities involve developing standardized, validated, and more affordable MRD assays, along with strategic collaborations between biotech firms and research institutions for innovation acceleration.

However, market growth faces challenges such as the high cost associated with MRD testing technologies, limited accessibility in developing regions, and the need for skilled personnel to interpret complex results. Additionally, regulatory hurdles and evolving guidelines can slow down the adoption of new MRD methodologies. For growth and innovation, focusing on artificial intelligence and machine learning integration into MRD data analysis could transform result interpretation, making it more accurate and user-friendly. Ultimately, the MRD testing market is evolving rapidly, with substantial potential for growth if key barriers are addressed strategically.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Minimal Residual Disease Testing Market

The Minimal Residual Disease Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Need for refine treatment decisions for a variety of cancers
    • Rising prevalence of hematologic malignancies among world population
  • Market Restraints
    • High cost associated with the MRD testing
  • Market Opportunities
    • Evolution of personalized MRD testing techniques
    • Ongoing development of new minimal residual disease testing methods
  • Market Challenges
    • Stringent government regulations for the commercialization of MRD

Porter's Five Forces: A Strategic Tool for Navigating the Minimal Residual Disease Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Minimal Residual Disease Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Minimal Residual Disease Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Minimal Residual Disease Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Minimal Residual Disease Testing Market

A detailed market share analysis in the Minimal Residual Disease Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Minimal Residual Disease Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Minimal Residual Disease Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Minimal Residual Disease Testing Market

A strategic analysis of the Minimal Residual Disease Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Minimal Residual Disease Testing Market, highlighting leading vendors and their innovative profiles. These include Adaptive Biotechnologies Corporation, Agilus Diagnostics Ltd., Amgen Inc., ARUP Laboratories, AstraZeneca PLC, Asuragen Inc. by Bio-Techne Corporation, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, C2I Genomics Inc., Cergentis B.V., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Genetron Holdings Limited, GRAIL, LLC by Illumina, Inc., Guardant Health, Inc., Integrated DNA Technologies, Inc., Invivoscribe, Inc., Kite Pharma, Inc. by Gilead Sciences, Inc., Laboratory Corporation of America Holdings, Mdxhealth BV, MedGenome Inc, Mission Bio, Inc., Myriad Genetics, Inc., Natera Inc., NeoGenomics Laboratories, Inc., OPKO Health, Inc., Quest Diagnostics incorporated, Sysmex Corporation, and Veracyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Minimal Residual Disease Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Flow Cyclometry, Next-Generation Sequencing, and Polymerase Chain Reaction.
  • Based on Indication, market is studied across Leukemia, Lymphoma, and Myeloma.
  • Based on End-User, market is studied across Academic & Research Institutes, Diagnostic Laboratories, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Need for refine treatment decisions for a variety of cancers
      • 5.1.1.2. Rising prevalence of hematologic malignancies among world population
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the MRD testing
    • 5.1.3. Opportunities
      • 5.1.3.1. Evolution of personalized MRD testing techniques
      • 5.1.3.2. Ongoing development of new minimal residual disease testing methods
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations for the commercialization of MRD
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Minimal Residual Disease Testing Market, by Technology

  • 6.1. Introduction
  • 6.2. Flow Cyclometry
  • 6.3. Next-Generation Sequencing
  • 6.4. Polymerase Chain Reaction

7. Minimal Residual Disease Testing Market, by Indication

  • 7.1. Introduction
  • 7.2. Leukemia
  • 7.3. Lymphoma
  • 7.4. Myeloma

8. Minimal Residual Disease Testing Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Diagnostic Laboratories
  • 8.4. Hospitals

9. Americas Minimal Residual Disease Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Minimal Residual Disease Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Minimal Residual Disease Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adaptive Biotechnologies Corporation
  • 2. Agilus Diagnostics Ltd.
  • 3. Amgen Inc.
  • 4. ARUP Laboratories
  • 5. AstraZeneca PLC
  • 6. Asuragen Inc. by Bio-Techne Corporation
  • 7. Bio-Rad Laboratories, Inc.
  • 8. Bristol-Myers Squibb Company
  • 9. C2I Genomics Inc.
  • 10. Cergentis B.V.
  • 11. Exact Sciences Corporation
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Genetron Holdings Limited
  • 14. GRAIL, LLC by Illumina, Inc.
  • 15. Guardant Health, Inc.
  • 16. Integrated DNA Technologies, Inc.
  • 17. Invivoscribe, Inc.
  • 18. Kite Pharma, Inc. by Gilead Sciences, Inc.
  • 19. Laboratory Corporation of America Holdings
  • 20. Mdxhealth BV
  • 21. MedGenome Inc
  • 22. Mission Bio, Inc.
  • 23. Myriad Genetics, Inc.
  • 24. Natera Inc.
  • 25. NeoGenomics Laboratories, Inc.
  • 26. OPKO Health, Inc.
  • 27. Quest Diagnostics incorporated
  • 28. Sysmex Corporation
  • 29. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. MINIMAL RESIDUAL DISEASE TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. MINIMAL RESIDUAL DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MINIMAL RESIDUAL DISEASE TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYCLOMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. MINIMAL RESIDUAL DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2023